These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 33358743

  • 21. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
    Aref S, Azmy E, El Ghannam D, Haroun M, Ibrahim L, Sabry M.
    Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762
    [Abstract] [Full Text] [Related]

  • 22. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
    Mohammadi S, Ghaffari SH, Shaiegan M, Zarif MN, Nikbakht M, Akbari Birgani S, Alimoghadam K, Ghavamzadeh A.
    Life Sci; 2016 May 01; 152():190-8. PubMed ID: 27063991
    [Abstract] [Full Text] [Related]

  • 23. [Characteristic and prognostic significance of leukemia stem cells associated antigens expressions in t (8;21) acute myeloid leukemia].
    Dao FT, Yang L, Wang YZ, Chang Y, Jiang Q, Jiang H, Liu YR, Huang XJ, Qin YZ.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Oct 14; 40(10):831-836. PubMed ID: 31775482
    [Abstract] [Full Text] [Related]

  • 24. Prognostic Impact and Phenotype of Residual Acute Myeloid Leukemia Stem Cells.
    Jaddaoui S, Bencharef H, Lamchahab M, Quessar A, Oukkache B.
    Clin Lab; 2022 Jun 01; 68(6):. PubMed ID: 35704721
    [Abstract] [Full Text] [Related]

  • 25. SS30, a novel thioaptamer targeting CD123, inhibits the growth of acute myeloid leukemia cells.
    Wang M, Wu H, Duan M, Yang Y, Wang G, Che F, Liu B, He W, Li Q, Zhang L.
    Life Sci; 2019 Sep 01; 232():116663. PubMed ID: 31323275
    [Abstract] [Full Text] [Related]

  • 26. [The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts].
    Yue WQ, Tang GS, Liu M, Cheng H, Ding J, Wang T, Wang JM, Hu XX, Zhang WP, Chen L, Yang JM.
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct 14; 38(10):876-882. PubMed ID: 29166741
    [Abstract] [Full Text] [Related]

  • 27. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, De Bardi M, Gargano F, Maurillo L, Divona M, Noguera NI, Consalvo MI, Borsellino G, Bernardi G, Amadori S, Venditti A, Battistini L, Lo-Coco F.
    Clin Cancer Res; 2015 Sep 01; 21(17):3977-85. PubMed ID: 25957287
    [Abstract] [Full Text] [Related]

  • 28. Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia.
    Kamel AM, Elsharkawy NM, Kandeel EZ, Hanafi M, Samra M, Osman RA.
    Front Oncol; 2022 Sep 01; 12():867684. PubMed ID: 35530356
    [Abstract] [Full Text] [Related]

  • 29. Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Yabushita T, Satake H, Maruoka H, Morita M, Katoh D, Shimomura Y, Yoshioka S, Morimoto T, Ishikawa T.
    Leuk Lymphoma; 2018 Sep 01; 59(9):2144-2151. PubMed ID: 29251166
    [Abstract] [Full Text] [Related]

  • 30. CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.
    Rollins-Raval M, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Boyiadzis M, Djokic M, Kant JA, Roth CG.
    Appl Immunohistochem Mol Morphol; 2013 May 01; 21(3):212-7. PubMed ID: 22914610
    [Abstract] [Full Text] [Related]

  • 31. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
    Tiribelli M, Raspadori D, Geromin A, Cavallin M, Sirianni S, Simeone E, Bocchia M, Fanin R, Damiani D.
    Leuk Res; 2017 Jul 01; 58():31-38. PubMed ID: 28407515
    [Abstract] [Full Text] [Related]

  • 32. Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity.
    Das N, Panda D, Gajendra S, Gupta R, Thakral D, Kaur G, Khan A, Singh VK, Vemprala A, Bakhshi S, Seth R, Sahoo RK, Sharma A, Rai S, Prajapati VK, Singh S.
    Int J Lab Hematol; 2024 Aug 01; 46(4):646-656. PubMed ID: 38456256
    [Abstract] [Full Text] [Related]

  • 33. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.
    Damiani D, Tiribelli M, Raspadori D, Sirianni S, Meneghel A, Cavalllin M, Michelutti A, Toffoletti E, Geromin A, Simeone E, Bocchia M, Fanin R.
    Oncotarget; 2015 Oct 06; 6(30):30212-21. PubMed ID: 26338961
    [Abstract] [Full Text] [Related]

  • 34. CD200 expression marks leukemia stem cells in human AML.
    Ho JM, Dobson SM, Voisin V, McLeod J, Kennedy JA, Mitchell A, Jin L, Eppert K, Bader G, Minden MD, Dick JE, Wang JCY.
    Blood Adv; 2020 Nov 10; 4(21):5402-5413. PubMed ID: 33147339
    [Abstract] [Full Text] [Related]

  • 35. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, Reilly RM.
    J Nucl Med; 2011 Sep 10; 52(9):1465-73. PubMed ID: 21816968
    [Abstract] [Full Text] [Related]

  • 36. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.
    Bras AE, de Haas V, van Stigt A, Jongen-Lavrencic M, Beverloo HB, Te Marvelde JG, Zwaan CM, van Dongen JJM, Leusen JHW, van der Velden VHJ.
    Cytometry B Clin Cytom; 2019 Mar 10; 96(2):134-142. PubMed ID: 30450744
    [Abstract] [Full Text] [Related]

  • 37. Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia.
    Arai N, Homma M, Abe M, Baba Y, Murai S, Watanuki M, Kawaguchi Y, Fujiwara S, Kabasawa N, Tsukamoto H, Uto Y, Ariizumi H, Yanagisawa K, Hattori N, Saito B, Shiozawa E, Harada H, Yamochi-Onizuka T, Nakamaki T, Takimoto M.
    Int J Hematol; 2019 May 10; 109(5):539-544. PubMed ID: 30847774
    [Abstract] [Full Text] [Related]

  • 38. ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML.
    Tiribelli M, Geromin A, Cavallin M, Di Giusto S, Simeone E, Fanin R, Damiani D.
    Eur J Haematol; 2017 Sep 10; 99(3):269-274. PubMed ID: 28618016
    [Abstract] [Full Text] [Related]

  • 39. ENPP4 and HOXA3 as potential leukaemia stem cell markers in acute myeloid leukaemia.
    Mohd Amin A, Panneerselvan N, Md Noor S, Mohtaruddin N, Sathar J, Norbaya WS, Osman R, Kee LH, Mohd Yaakub WH, Cheong SK, Abdullah M.
    Malays J Pathol; 2023 Apr 10; 45(1):65-76. PubMed ID: 37119247
    [Abstract] [Full Text] [Related]

  • 40. [Determination of leukemia stem cells in childhood acute myeloid leukemia and its clinical significance].
    Wang D, Tang YM, Xu XJ, Shen HQ, Qian BQ.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug 10; 18(4):952-8. PubMed ID: 20723307
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.